Abstract
The field of cancer immunotherapy has moved forward drastically in the past 20 years, since many tumorassociated antigens (TAA) have been identified. Although various approaches for therapeutic cancer immunotherapies, including peptide-based vaccines, have been developed and clinically examined, the complexity and diversity of tumor cell characteristics and host immune cell repertoires seem to limit the therapeutic efficacy of this treatment modality. Considering the diversity of immune responses against heterogeneous tumor cells, tailored selections of vaccine antigens appropriate for individual patients could be a rational approach for developing effective cancer vaccines. We have developed a novel immunotherapeutic approach called personalized peptide vaccine (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine peptides were selected based on the pre-existing host immunity before vaccination. We conducted a series of phase I and phase II clinical trials of PPV, which have shown better antigen-specific immune responses and promising clinical outcomes in patients with various types of advanced cancers. Further randomized phase III trials would be recommended to prove the clinical benefits of PPV. In addition, novel biomarkers for selecting patients who would benefit most from PPV remain to be identified.
Keywords: Advanced cancer, biomarker, cancer immunotherapy, clinical trial, peptide epitope, personalized peptide vaccine.
Current Medicinal Chemistry
Title:Personalized Peptide Vaccine for Treatment of Advanced Cancer
Volume: 21 Issue: 21
Author(s): Tetsuro Sasada, Akira Yamada, Masanori Noguchi and Kyogo Itoh
Affiliation:
Keywords: Advanced cancer, biomarker, cancer immunotherapy, clinical trial, peptide epitope, personalized peptide vaccine.
Abstract: The field of cancer immunotherapy has moved forward drastically in the past 20 years, since many tumorassociated antigens (TAA) have been identified. Although various approaches for therapeutic cancer immunotherapies, including peptide-based vaccines, have been developed and clinically examined, the complexity and diversity of tumor cell characteristics and host immune cell repertoires seem to limit the therapeutic efficacy of this treatment modality. Considering the diversity of immune responses against heterogeneous tumor cells, tailored selections of vaccine antigens appropriate for individual patients could be a rational approach for developing effective cancer vaccines. We have developed a novel immunotherapeutic approach called personalized peptide vaccine (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine peptides were selected based on the pre-existing host immunity before vaccination. We conducted a series of phase I and phase II clinical trials of PPV, which have shown better antigen-specific immune responses and promising clinical outcomes in patients with various types of advanced cancers. Further randomized phase III trials would be recommended to prove the clinical benefits of PPV. In addition, novel biomarkers for selecting patients who would benefit most from PPV remain to be identified.
Export Options
About this article
Cite this article as:
Sasada Tetsuro, Yamada Akira, Noguchi Masanori and Itoh Kyogo, Personalized Peptide Vaccine for Treatment of Advanced Cancer, Current Medicinal Chemistry 2014; 21 (21) . https://dx.doi.org/10.2174/0929867321666140205132936
DOI https://dx.doi.org/10.2174/0929867321666140205132936 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From Orphan Targets to Innovative New Antibiotic Drugs
Current Medicinal Chemistry Area, Age and Gender Dependence of the Nucleoside System in the Brain: a Review of Current Literature
Current Topics in Medicinal Chemistry Bioadhesive Films as Drug Delivery Systems
Drug Delivery Letters Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Anti-Tubercular and Anti-Inflammatory Activities of Azetidin-2-One Derivatives and Their Effects on the Activity of Phospholipase A2
Medicinal Chemistry Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Multi-target Pharmacological Effects of Platycodin D
Mini-Reviews in Organic Chemistry Editorial [Hot Topic: Drug Targets in Viral Infections (Guest Editor: Jean-Marc Sabatier)]
Infectious Disorders - Drug Targets Meet Our Editorial Board Member:
Current Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation Cellular Reservoirs of HIV-1 and their Role in Viral Persistence
Current HIV Research Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review
Current Neuropharmacology Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents